Legal Document View

Unlock Advanced Research with PRISMAI

- Know your Kanoon - Doc Gen Hub - Counter Argument - Case Predict AI - Talk with IK Doc - ...
Upgrade to Premium
[Cites 3, Cited by 0]

Custom, Excise & Service Tax Tribunal

Yeluri Formulations Pvt Ltd vs Hyderabad-I on 13 March, 2019

                                     (1)                  Appeal No. E/1293/2011
                                                                     E/1302/2011




     CUSTOMS, EXCISE AND SERVICE TAX APPELLATE TRIBUNAL
               REGIONAL BENCH AT HYDERABAD
                                  Division Bench
                                     Court - I


                   APPEALs No. E/1293/2011 & E/1302/2011
      (Arising out of Orders-in-Appeal Nos. 90/2010 (H-I)CE, dated 30.12.2010 and
     91/2010 (H-I)CE, dated 30.12.2010 passed by CCCE&ST (Appeals-I), Hyderabad)



YELURI FORMULATIONS LIMITED                      ..               APPELLANT(s)
                                           Vs.
CCCE&ST, Hyderabad-I                             ..             RESPONDENT(s)


Appearance
Shri B. Seshagiri Rao, Advocate for the appellant
Shri C. Mallikharjun Reddy, Superintendent/AR for the Respondent.


Coram:
Hon'ble Mr. M.V. RAVINDRAN, MEMBER (JUDICIAL)

Hon'ble Mr. P.V. SUBBA RAO, MEMBER (TECHNICAL)



                                                      Date of Hearing: 06.02.2019
                                                      Date of Decision: 13.03.2019


                    FINAL ORDER No. A/30332-30333/2019



[Order per: Mr. P. Venkata Subba Rao)


1.      These two appeals are against Orders-in-Appeal as stated herein

above. Both these appeals are on the same issue and hence are disposed

of together.
                                  (2)                Appeal No. E/1293/2011
                                                               E/1302/2011




2.   Ld. Counsel for the appellant submits that the short point to be

decided in both these appeals is whether the appellants are liable to pay

Central Excise Duty on physician samples which they had sold to their

distributors on the basis of transaction value under section 4A of Central

Excise Act, 1944. The appellants herein are engaged in the manufacture of

P & P medicines falling under Chapter 30. They were issued show cause

notices proposing recovery of Central Excise Duty invoking the extended

period of time and proposing penalties under section 11 AC of Central

Excise Act, 1944.        Ld. Counsel submits that they manufacture

pharmaceuticals both on their own account and as job workers. As they

are a small manufacturers they cannot afford to supply physician samples

free of cost. However, their Dealers and Distributors find it necessary to

distribute samples free of cost to the physicians in order to market the

products and expand their own market.            Therefore, they have an

arrangement according to which they manufacture physician samples

clearly marked as physician samples but these samples are sold by them to

their distributors who, in turn, supply them free of cost to the doctors. They

have discharged service tax on these physician samples as per the

transaction value. There is no retail price on these samples because these

samples cannot be sold. However, there is a price on which they have sold

these samples to their dealers which is the transaction value on which they

paid the Central Excise Duty.
                                  (3)                Appeal No. E/1293/2011
                                                               E/1302/2011




3.     It is the case of the Department that physician samples should be

charged to Central Excise Duty as per the price of corresponding goods

which are sold in the market, as has been held by Hon'ble High Court of

Bombay in the case of Indian Drugs Manufacturers' Association

[2008(222)ELT 22 (HC-Mum.)] and CBEC Circular No. 813/10/2005-CX,

dated 25.04.2005. It is the case of the appellant that they are liable to pay

Central Excise Duty as per the transaction value wherever the samples

were sold by them. The Department demanded duty invoking the extended

period, holding that they have not disclosed that they were clearing

physician samples valuating them at Section 4 instead of Section 4A as

required in their ER-1 returns, thereby they have deliberately suppressed

their under valuation. The appellant contests this matter both on merits and

on limitation.




4.     Ld. DR reiterates the findings of the first appellate authority.   He

draws the attention of the Bench to paras 9 to 12 of the impugned order in

which he clarified the reasons for not accepting the contentions of the

appellant as follows:



 (i)    The purchase orders which were presented before him had the

        invoices which did not indicate that they were physician samples

        and not for sale.
                                   (4)                Appeal No. E/1293/2011
                                                                E/1302/2011




 (ii)    There is no cross reference between the invoices and payments as

         indicated in the Ledgers.      He concluded that physician samples

         were actually not being sold but were distributed free to their

         Distributors. He however observed that appellant was statutorily

         prohibited from selling physician samples under Rule 65(18) and

         Rule 95 and Rule 96(1)(ix) of Drugs & Cosmetics Rules and

         therefore their contention that they were selling physician samples

         is a complete mis-representation of the facts.



5.      He relied upon the Larger Bench decision of the Tribunal in the case

of Cadila Pharmaceuticals Limited vs. CCE, Ahmedabad-II [2008(232) ELT

245 (Tri.-LB)] and held that physician's samples have to be valued as per

Section 4A of Central Excise Act, 1944.



6.      We have considered the arguments on both sides and perused the

records. The question to be answered is how physician's samples should

be valued when the free samples are sold by the appellant to their

distributors and for which there is an invoice value. It is the case of the

department that physician samples cannot be sold and the assertion that

they are sold is incorrect because it violates the Drugs & Cosmetics Rules.

Therefore, physician's samples should be treated at par with the normal

goods and duty has to be charged proportionately as is applicable. Since

the pharmaceutical goods are covered under Section 4A of the Central

Excise Act, 1944 as has been decided by Hon'ble High Court of Mumbai in
                                           (5)                      Appeal No. E/1293/2011
                                                                              E/1302/2011




the case of Indian Drugs Manufacturers' Association (supra), Central

Excise duty should be charged under section 4A.                           The first appellate

authority also observed that appellant has not produced invoices to show

that they are actually sold physician samples. Learned Counsel for the

appellant produced a letter dated 25.01.2006 from Sriven Pharma to M/s

Yeluri Formulations Pvt. Ltd. detailing the payments made with respect to

invoices covering physician samples.



7.    We find that this question as to how to value physician samples which

are sold and not supplied free was answered in the case of Parnax Lab.

Pvt. Ltd. vs. CCE, Vapi [2012(278)E.L.T. 95 (Tri.-Ahmd.)] (in which one of

us Shri M.V. Ravindran was a Member), paras 7 to 9 of this order are

reproduced:




     "7.   As regards the physician samples manufactured by the appellant for other
     principals and sold the same to them under contractual obligations, it is seen that the
     said contracts have not been challenged by the Revenue in the proceedings initiated
     by the show cause notice. It is also noticed that the transaction value which has been
     declared by the appellant while clearing the goods from their factory premises has
     not been rejected. It is also not in dispute that the appellant has been discharging the
     duty liability on the said physician samples as per the invoices raised from his
     factory and cleared to the principal manufacturer who in turn distributes the very
     same to the medical profession. On this back ground, we find that the judgment of
     this Bench in the case of Sidmak Laboratories (India) Ltd. is squarely on the point.
     The issue involved in that case was the first appellate authority has held that the
     samples cleared from the factory premises of the assessee therein were not being
     cleared for free distribution but are being sold at factory gate and the whole sale price
     is available at the factory gate. It is also seen that in that case there was no dispute
     about the factual position that the samples were being sold, this bench held that the
                                         (6)                         Appeal No. E/1293/2011
                                                                               E/1302/2011



value of the sample should be in terms of Section 4. Aggrieved by such an order, the
Revenue preferred Civil Appeal before the Apex Court in appeal No. D/1456/09. The
said appeal was dismissed by Apex Court [2011 (270) E.L.T. A90 (S.C.)] by
recording as under :




                            IN THE SUPREME COURT OF INDIA
                             CIVIL APPELLATE JURISDICTION
                               CIVIL APPEAL NO. OF 2009
                                   (D. NO. 1456 OF 2009)

COMMISSIONER OF CENTRAL EXCISE, DAMAN                                  ...APPELLANT
                                         VERSUS

M/S. SIDMAK LABORATORIES (I) LTD.                                   ...RESPONDENT

                                          ORDER

Delay condoned.

The Civil Appeals are dismissed.

sd/-

.......................


                                                        (S.H. KAPADIA)


                         New Delhi,                          sd/-

                                                      .........................

                        July 27, 2009                 (AFTAB ALAM)

8. It can be said that the ratio laid down by the Bench for the case of M/s. Sidmak Laboratories (I) Ltd. is upheld by the Apex Court hence we are of the considered view that the demand of the duty liability on the physician samples sold by the appellant to the principals, the assessable value as ascertained by the assessee and the duty liability discharged is correct and there is no reason for recalculating the assessable value based upon the value arrived at on pro rata basis of sales pack.

9. As regards the physician samples manufactured and cleared by the appellant of their own product, we agree with the learned DR that on merits the issue is covered against the assessee by the Larger Bench decision of this Tribunal in the case of Cadila Pharmaceuticals Ltd. (supra)."

                                  (7)                Appeal No. E/1293/2011
                                                               E/1302/2011




8. The circular issued by the Board relied upon by the Department as well as the Case laws on Indian Drug Manufacturers' Association and others shows that physician samples were not sold but were supplied free of cost and hence there was no transaction value. The present case is similar to the case of Parnax Lab Pvt. Ltd. (supra) in which there is a transaction value because the physician samples were sold by the manufacturer to the Distributor who in turn supplied them at free of cost to the Doctors. We have also considered the findings of the first appellate authority that selling physician samples is violative of Drugs & Cosmetic Rules, 1945. This is an issue which may have to be looked into by the State Drugs Controller/Drug Controller of India but where there is a transaction value, the same cannot be ignored. Once the samples are sold and there is a transaction value, the price at which they are sold forms the assessable value and the assessment has to be done. Therefore, no differential duty can be charged, holding that Section 4A should be applied even in cases where the appellant has sold the physician samples. On the factual position whether the physician samples were actually sold or otherwise, the matter needs to be verified by the adjudicating authority after giving the appellant an opportunity to present the documents. In view of the above, the appeal is disposed of as below:

The impugned order is modified to the extent setting aside the demand in respect of the invoices where the appellant is able to (8) Appeal No. E/1293/2011 E/1302/2011 provide documentary evidence to the adjudicating authority to substantiate their claim that physician samples were sold by them and not at free of cost. The demand in respect of those cases where the appellant is not able to substantiate their claim along with interest is sustained. All penalties are set aside.

(Pronounced in open Court on 13.03.2019) (P.VENKATA SUBBA RAO) (M.V. RAVINDRAN) MEMBER (TECHNICAL) MEMBER (JUDICIAL) Vrg